Study of Low-level Laser Therapy in the Acute Treatment of Migraine
Primary Purpose
Migraine Headache
Status
Unknown status
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Argus Migraine Treatment device
Sponsored by
About this trial
This is an interventional treatment trial for Migraine Headache
Eligibility Criteria
Inclusion Criteria
- male or female
- aged 18 or older;
- subject diagnosed with migraine according to The International Classification of Headache Disorders- Version 3;
- 1-20 headache days per month;
- history of at least moderate pain if migraine left untreated.
Exclusion Criteria:
- headache on greater than 25 days/month on average for preceding 3 months;
- headache on greater than 25 days in present month;
- headache attributed to: head or neck trauma, cluster headache, specific migraine variants such as basilar artery, ophthalmoplegic, hemiplegic, etc;
- women of child bearing age not using acceptable method of contraception;
- pregnant or nursing women;
- history of malignancy of any organ
- uncontrolled: hypertension, severe psychiatric disorders, or known use of narcotics, analgesic or alcohol abuse;
- light sensitivity;
- retinal disease;
- intranasal pathology.
Sites / Locations
- San Francisco Clinical Research CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Sham Comparator
Active Comparator
Arm Label
Sham
Treatment
Arm Description
Sham low energy laser using approximately 1/1000 th energy of treatment laser.
Treatment laser.
Outcomes
Primary Outcome Measures
Differences between treatment groups in pain free rates at 2 hours post treatment.
Secondary Outcome Measures
Full Information
NCT ID
NCT02969642
First Posted
October 20, 2016
Last Updated
December 1, 2016
Sponsor
The San Francisco Clinical Research Center
1. Study Identification
Unique Protocol Identification Number
NCT02969642
Brief Title
Study of Low-level Laser Therapy in the Acute Treatment of Migraine
Official Title
A Single-center, Sham-controlled, Single Attack Study of Laser Therapy to the Sphenopalatine Ganglion (SPG) in the Acute Treatment of Migraine
Study Type
Interventional
2. Study Status
Record Verification Date
December 2016
Overall Recruitment Status
Unknown status
Study Start Date
March 2016 (undefined)
Primary Completion Date
May 2017 (Anticipated)
Study Completion Date
July 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The San Francisco Clinical Research Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study evaluates the treatment of migraine pain using low energy laser light to quench migraine signals issuing from the sphenopalatine ganglion (SPG).
Detailed Description
This is a double blinded, two arm study, comprising a sham laser and a treatment laser. The sham laser emits approximately 1/1000 the energy of the treatment laser.
It is presumed that pain relief from the treatment laser is achieved by exhausting the release of neurotransmitters from the SPG following laser stimulation. Subjects will be treated and subsequently queried at time intervals for their self-assessment of pain score (VAS). The time intervals include queries at 5 minutes through 2 hours post treatment. Subjects will be further contacted 24 hours and one month post treatment. Adverse events will be monitored and recorded.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine Headache
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Sham
Arm Type
Sham Comparator
Arm Description
Sham low energy laser using approximately 1/1000 th energy of treatment laser.
Arm Title
Treatment
Arm Type
Active Comparator
Arm Description
Treatment laser.
Intervention Type
Device
Intervention Name(s)
Argus Migraine Treatment device
Other Intervention Name(s)
low energy laser therapy
Intervention Description
treatment of Migraines targeting Sphenopalatine ganglion
Primary Outcome Measure Information:
Title
Differences between treatment groups in pain free rates at 2 hours post treatment.
Time Frame
2 hours post treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria
male or female
aged 18 or older;
subject diagnosed with migraine according to The International Classification of Headache Disorders- Version 3;
1-20 headache days per month;
history of at least moderate pain if migraine left untreated.
Exclusion Criteria:
headache on greater than 25 days/month on average for preceding 3 months;
headache on greater than 25 days in present month;
headache attributed to: head or neck trauma, cluster headache, specific migraine variants such as basilar artery, ophthalmoplegic, hemiplegic, etc;
women of child bearing age not using acceptable method of contraception;
pregnant or nursing women;
history of malignancy of any organ
uncontrolled: hypertension, severe psychiatric disorders, or known use of narcotics, analgesic or alcohol abuse;
light sensitivity;
retinal disease;
intranasal pathology.
Facility Information:
Facility Name
San Francisco Clinical Research Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jerome Goldstein, MD
Phone
415-673-4600
Email
JGoldstein@sfcrc.org
First Name & Middle Initial & Last Name & Degree
Jerome Goldstein, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Study of Low-level Laser Therapy in the Acute Treatment of Migraine
We'll reach out to this number within 24 hrs